Las Vegas, NV & Vancouver, BC – October 14, 2025 – Molecular You, a leader in molecular medicine and preventive health, will showcase its platform at HLTH 2025 from October 19 to 22, 2025, at the Venetian Expo Center in Las Vegas.
Molecular You measures over 250 biomarkers with a single blood test to identify health risks at their root cause earlier, before symptoms present. The platform utilizes artificial intelligence (AI) to conduct in-depth analysis and provides a comprehensive overview of an individual’s overall health, accompanied by personalized lifestyle recommendations to reduce disease risk.
“Rather than waiting until a disease has already taken hold, as traditional diagnostics take after a person becomes symptomatic, our platform assesses the underlying biological pathways that drive disease,” said Jim Kean, CEO of Molecular You. “The multi-omic analysis of proteomics and metabolomics Molecular You delivers is grounded in peer-reviewed science and is especially powerful in predicting complex conditions such as Alzheimer’s, PCOS, and autoimmune diseases.”
Measurement of multi-omic biomarkers has been demonstrated (Snyder 2013, Price 2017) to be more effective in detecting disease before symptoms appear. In a documented case, Molecular You detected stage 1 pancreatic cancer in a symptom-free patient, enabling curative surgery, long before it would otherwise have been detected, when it is often too late.
Molecular You has gained significant momentum in the past year and has been selected for inclusion in Fast Company’s prestigious “Next Big Things in Tech” list for 2025. This follows the successful launches in both the direct-to-consumer and clinical markets in the U.S. and Canada, as well as the signing of a major partnership with HealthQuest Esoterics.
The company also recently secured a $5 million Series A led by Voloridge Health and is developing its next-generation multi-omic assay, which will measure over 800 biomarkers, with plans for expansion into cancer diagnostics. The company also announced a strategic partnership with South Korea’s NKCL Bio Group to build a big data platform for early disease detection and personalized care, marking its first commercial deployment in Asia and a launchpad for regional expansion.
See a demonstration of the platform, speak to the team:
- Where: Venetian Level 2: Exhibit Hall, Diagnostics Zone, Booth V1050
- When: Monday & Tuesday: 8:00 AM – 5:45 PM, Wednesday: 8:00 AM – 12:00 PM
HLTH USA 2025 unites global health leaders to advance innovation in laboratory science and digital diagnostics. Molecular You will be featured in the Diagnostics Zone, alongside innovators transforming healthcare from reactive to proactive, cutting costs, boosting efficiency, and scaling data-driven solutions.
-##-
About Molecular You
Molecular You measures over 250 biomarkers with a single blood test using advanced proteomics and metabolomics to identify health risks at their root cause. Its AI-powered platform delivers personalized assessments and insights, along with actionable recommendations for over 26 health conditions, to support longevity, chronic disease management, and early disease prevention. Both individuals and clinical practices increasingly leverage Molecular You to maximize personal and patient health outcomes through predictive, preventive, and precision medicine. Learn more: https://www.molecularyou.com/
View Similar Articles